Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and clinical settings, as well as in vitro synergism with several anticancer agents. Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5295419/
https://ncbi.nlm.nih.gov/pubmed/27494885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10983
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items